The potential of lasmiditan in migraine

Lasmiditan, a highly selective 5-hydroxytryptamine receptor 1F (5-HT(1F)) agonist, is the first drug in its class and is lacking triptan-like vasoactive properties. The US Food and Drug Administration (FDA) has recently approved lasmiditan for the acute treatment of migraine in adults based on posit...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ther Adv Neurol Disord
Hlavní autoři: Mecklenburg, Jasper, Raffaelli, Bianca, Neeb, Lars, Sanchez del Rio, Margarita, Reuter, Uwe
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2020
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7739205/
https://ncbi.nlm.nih.gov/pubmed/33403005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286420967847
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky